YM17E
CAS No. 124900-72-7
YM17E( —— )
Catalog No. M26512 CAS No. 124900-72-7
YM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.
YM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 101 | Get Quote |
|
10MG | 141 | Get Quote |
|
25MG | 235 | Get Quote |
|
50MG | 347 | Get Quote |
|
100MG | 518 | Get Quote |
|
500MG | 1134 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameYM17E
-
NoteResearch use only, not for human use.
-
Brief DescriptionYM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.
-
DescriptionYM17E is an inhibitor of ACAT with IC50 of 44 nM in rabbit liver microsomes in vitro.(In Vitro):YM17E is potent in inhibiting ACAT activity in the intestine with IC50 of 34 nM.(In Vivo):YM17E inhibits the production of [14C]cholesteryloleate from [14C]oleoyl CoA in a dose-dependent manner in both liver and intestinal microsomes used as enzyme sources. YM17E (3, 5, 10 mg/kg, i.v.) significantly inhibits hepatic ACAT activities in a dose-dependent manner. YM17E (oral; i.v.) produces a significant increase in 125I-LDL clearance in atherogenic diet-fed rats. YM17E (3, 10, 30 mg/kg; p.o.) decreases total cholesterol, cholesteryl ester, and non-HDL cholesterol in a dose-dependent manner. YM17E (oral) decreases total cholesterol and cholesteryl ester levels in the liver significantly in a dose-dependent manner.
-
In VitroYM17E is as potent in inhibiting ACAT activity in the liver as in the intestine, with IC50 values of 45 and 34 nM, respectively.
-
In VivoYM17E (3, 10 and 30 mg/kg per day, p.o.) decreases total cholesterol, cholesteryl ester and non-HDL cholesterol in a dose-dependent manner. Total cholesterol and cholesteryl ester levels in liver do not decrease significantly after intravenous administration of YM17E, but do decrease significantly and in a dose-dependent manner after oral administration. YM17E (3, 5, 10 mg/kg, i.v.) significantly inhibits hepatic ACAT activities in a dose-dependent manner. YM17E produces a significant increase in 125I-LDL clearance in atherogenic diet-fed rats after both oral and intravenous administration. YM17E inhibits production of [14C]cholesteryloleate from [14C]oleoyl CoA in a dose-dependent manner in both liver and intestinal microsomes used as enzyme sources.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorHCV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number124900-72-7
-
Formula Weight652.928
-
Molecular FormulaC40H56N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 125 mg/mL (191.45 mM)
-
SMILESCN(C)c1ccc(NC(=O)N(Cc2cccc(CN(C3CCCCCC3)C(=O)Nc3ccc(cc3)N(C)C)c2)C2CCCCCC2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Makonen Belema, et al. Hepatitis C virus inhibitors. US8329159B2.
molnova catalog
related products
-
Pyrazolo[1,5-a]pyrim...
Detail unknown.
-
Biotin-PEG2-OH
Biotin-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Lycobetaine
Ungeremine is a potential biofungicide against Penicillium roqueforti and Aspergillus niger.Ungeremine have strong antibacterial activity against Flavobacterium columnare.